Gallion H H, Maruyama Y, van Nagell J R, Donaldson E S, Rowley K C, Yoneda J, Beach J L, Powell D E, Kryscio R J
Cancer. 1987 May 15;59(10):1709-12. doi: 10.1002/1097-0142(19870515)59:10<1709::aid-cncr2820591005>3.0.co;2-v.
From January 1977 to July 1984, 32 patients with Stage IIIB cervical cancer were treated at the University of Kentucky Medical Center by a combination of outpatient neutron brachytherapy and external pelvic radiation. These patients received 4500 to 5000 rad external photon therapy and two or three outpatient Californium-252 (252Cf) implants, plus sidewall boost irradiation. Treatment results were compared retrospectively to those obtained in a historical control group of patients with Stage IIIB cervical cancer treated with external radiation and conventional photon brachytherapy from 1972 to 1976. Local or regional tumor recurrence developed in 53% of patients treated with neutron therapy and an additional 9% experienced distant metastases. Thirty-eight percent of patients remain free of disease 12 to 96 months (mean, 51 months) after therapy. The 2-year and 5-year survival rates of patients treated with neutron therapy were 53% and 36%, which were not significantly different than those obtained with photon brachytherapy (2-year survival, 61%; 5-year survival, 34%). Complications of neutron therapy were minimal and included proctitis (19%) and vaginal stenosis (9%). There were no cases of enteric fistulae. Outpatient neutron brachytherapy was cost effective and was well tolerated by patients.
1977年1月至1984年7月，肯塔基大学医学中心对32例IIIB期宫颈癌患者采用门诊中子近距离放疗与盆腔外照射相结合的方法进行治疗。这些患者接受了4500至5000拉德的外照射光子治疗以及两到三次门诊钔-252（252Cf）植入治疗，并辅以侧野增强照射。将治疗结果与1972年至1976年采用外照射和传统光子近距离放疗治疗的IIIB期宫颈癌患者历史对照组的结果进行回顾性比较。接受中子治疗的患者中，53%出现局部或区域肿瘤复发，另有9%发生远处转移。38%的患者在治疗后12至96个月（平均51个月）无疾病复发。接受中子治疗的患者2年和5年生存率分别为53%和36%，与光子近距离放疗的结果（2年生存率61%；5年生存率34%）无显著差异。中子治疗的并发症极少，包括直肠炎（19%）和阴道狭窄（9%）。无肠瘘病例。门诊中子近距离放疗具有成本效益，患者耐受性良好。
